JOURNAL OF PUBLIC HEALTH AND DISEASES
Integrity Research Journals
ISSN: 2705-2214
Model: Open Access/Peer Reviewed
DOI: 10.31248/JPHD
Start Year: 2018
Email: jphd@integrityresjournals.org
Spironolactone-digoxin synergizes gynecomastia: A case report
https://doi.org/10.31248/JPHD2020.056 | Article Number: E57E205E1 | Vol.3 (4) - August 2020
Received Date: 27 January 2020 | Accepted Date: 27 February 2020 | Published Date: 30 August 2020
Authors: S. M. Biradar* , B. Kohima , K. Purnagopinath , Sanjeev N. Bentoor , L. S. Patil and V. Vijayakumari
Keywords: Breast enlargement, drug- induced, male patients.
Gynecomastia refers to a proliferation of breast tissue in the males that causes imbalances in estrogen and androgen levels, resulting in increased or unopposed estrogen action on breast tissue, where underlying aetiology might be physiological or pathological. Approximately 10 to 25% cases of gynecomastia are in associated with drugs. There are many drugs (Spironolactone, Furosemide, Digoxin etc.) capable to induce gynecomastia on individual basis, but practically it is not seen often. Simultaneously, when two or more similar drugs (capable to induce gynacomastia) are administered concomitantly, it is seen often for its synergistic side effect as a drug induced gynecomastia. In the present case study, a 65 years old male patient who had been taking Digoxin and Spironolactone for Ischemic Heart Disease (IHD) with Left Ventricular Failure (LVEF) in the past one year. On his regular follow up, it has been observed/noticed that the patient has developed a gynecomastia. Hence, it is presumed that the drug induced gynecomastia may be due to synergistic side effect of Spironolactone and Digoxin per se.
| Almah, U., Haseeen, M. A., & Rahman, S. Z. (2009). Gynecomastia: An ADR due to drug interaction. Indian Journal of Pharmacology, 41(6), 286-287. Crossref |
||||
| Başaran, Y., Ünal, H. U., Taşlipinar, A., Bolu, S. E. (2009). Digoxin induced gynecomastia: Case report. Turkiye Klinikleri Journal of Endocrinology, 3(4), 104-106. | ||||
| Biggar, R. J. (2012). Molecular pathways: Digoxin use and estrogen-sensitive cancers-risks and possible therapeutic implications. Clinical Cancer Research, 18(8), 2133-2137. Crossref |
||||
| Fauci, A. S., Kasper, D., Hauser, S. L., Harrison T. R. (2018). Harrison's principles of internal medicine, 20th edition Part 12; Pp. 2779-2781. | ||||
| Innocenti, A., Ghezzi, S., & Innocenti, M. (2019). Correction of tuberous nipple areolar complex deformity in gynecomastia: The deformity that can get forgotten. Annals of Plastic Surgery, 83(3), 367. Crossref |
||||
| Kauser M. M., KasiJagadeesh, M., Kumaraswamy, R. C., Manoj Kumar, M., & Jagadeesh, K. V. (2014). Spironolactone/digoxin induced gynecomastia: A comparative case study. World Journal of Pharmaceutical Research, 3(6), 1014-1018. | ||||
| Saboori, F., & Behzadnia, M. J. (2019). Gynecomastia, as an extremely rare presentation of chest wall lymphoma, a case report and review the articles. Acta Medica Iranica, 57(4), 276-279. | ||||
| Veeregowda, S. H., Krishnamurthy, J. J., Krishnaswamy, B., & Narayana, S. (2018). Spironolactone-induced unilateral gynecomastia. International Journal of Applied and Basic Medical Research, 8(1), 45-47. Crossref |
||||
Copyright © 2026 Integrity Research Journals. All rights reserved.